King's College London, Institute of Psychiatry, Psychology and Neuroscience, De Crespigny Park, London, UK.
South London and Maudsley NHS Foundation Trust, London, UK.
Eur J Epidemiol. 2021 Jan;36(1):89-101. doi: 10.1007/s10654-020-00643-2. Epub 2020 May 15.
Antipsychotic treatments are associated with safety concerns in people with dementia. The authors aimed to investigate whether risk of adverse outcomes related to antipsychotic prescribing differed according to major neuropsychiatric syndromes-specifically psychosis, agitation, or a combination. A cohort of 10,106 patients with a diagnosis of dementia was assembled from a large dementia care database in South East London. Neuropsychiatric symptoms closest to first dementia diagnosis were determined according to the Health of the Nation Outcome Scales' mental and behavioural problem scores and the sample was divided into four groups: 'agitation and psychosis', 'agitation, but no psychosis', 'psychosis, but no agitation', and 'neither psychosis nor agitation'. Antipsychotic prescription in a one-year window around first dementia diagnosis was ascertained as exposure variable through natural language processing from free text. Cox regression models were used to analyse associations of antipsychotic prescription with all-cause and stroke-specific mortality, emergency hospitalisation and hospitalised stroke adjusting for sixteen potential confounders including demographics, cognition, functioning, as well as physical and mental health. Only in the group 'psychosis, but no agitation' (n = 579), 30% of whom were prescribed an antipsychotic, a significant antipsychotic-associated increased risk of hospitalised stroke was present after adjustment (adjusted hazard ratio (HR) 2.16; 95% confidence interval (CI) 1.09-4.25). An increased antipsychotic-related all-cause (adjusted HR 1.14; 95% CI 1.04-1.24) and stroke-specific mortality risk (adjusted HR 1.28; 95% CI 1.01-1.63) was detected in the whole sample, but no interaction between the strata and antipsychotic-related mortality. In conclusion, the adverse effects of antipsychotics in dementia are complex. Stroke risk may be highest when used in patients presenting with psychosis without agitation, indicating the need for novel interventions for this group.
抗精神病药物治疗与痴呆患者的安全问题有关。作者旨在研究抗精神病药物处方相关的不良结果风险是否因主要神经精神综合征(具体为精神病、激越或两者的组合)而异。一个由伦敦东南部一个大型痴呆护理数据库中的 10106 名痴呆患者组成的队列。根据《国民健康结果量表》的精神和行为问题评分,确定与首次痴呆诊断最接近的神经精神症状,并将样本分为四组:“激越和精神病”、“激越,但无精神病”、“精神病,但无激越”和“既无精神病也无激越”。通过自然语言处理从自由文本中确定首次痴呆诊断前后一年窗口期内的抗精神病药物处方作为暴露变量。使用 Cox 回归模型分析抗精神病药物处方与全因和卒中特异性死亡率、急诊住院和住院卒中的关联,调整了 16 个潜在混杂因素,包括人口统计学、认知、功能以及身体和心理健康。只有在“精神病,但无激越”组(n=579)中,30%的患者被开了抗精神病药物,调整后抗精神病药物与住院卒中风险增加显著相关(调整后的危险比(HR)2.16;95%置信区间(CI)1.09-4.25)。在整个样本中,抗精神病药物相关的全因(调整 HR 1.14;95% CI 1.04-1.24)和卒中特异性死亡率风险(调整 HR 1.28;95% CI 1.01-1.63)增加,但各层与抗精神病药物相关死亡率之间没有相互作用。总之,抗精神病药物在痴呆中的不良影响是复杂的。当用于没有激越的精神病患者时,卒中风险可能最高,这表明需要为这一人群提供新的干预措施。